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Abstract  
Introduction: Ultrasound (US) is the imaging modality of choice for staging the axilla prior to 
surgery in patients with breast cancer (BC). High pathological complete response rates in the axilla 
after NACT mean a more conservative approach to surgery can be considered. Radiological re-staging 
is important in this decision making. After the presentation of results from ACOSOG Z1071 in 
December 2012, formal ultrasound re-assessment of the axilla after primary therapy was specifically 
requested in our institution. We report on the accuracy of axillary US (aUS) for identifying residual 
axillary disease post-NACT.  
Methods: Data were collected on patients who had proven axillary disease prior to NACT and 
underwent axillary lymph node dissection after NACT between January 2013 and December 2015. 
Post-chemotherapy aUS reports and axillary pathology reports were classified as positive or negative 
for abnormal lymph nodes and for residual disease (cCR and pCR respectively).  
Results: The sensitivity and specificity of aUS was 71% and 88% respectively. The negative 
predictive value (NPV) was 83%. The false negative rate was 29%. 
Conclusions: Axillary ultrasound provides clinically useful information post-NACT, which will 
guide surgical decision-making. Patients with aUS-negative axillae are likely to have a lower false 
negative rate of SLNB after NACT (Boughey et al). However, aUS does not replace the need to 
identify and biopsy the nodes which were proven to be positive prior to NACT.  
 
 
 
 
 
 
  
Introduction 
 The advent of Sentinel Lymph Node Biopsy (SLNB) represented a radical change in the surgical 
management of early breast cancer. In that setting it provides adequate staging while allowing 
node negative patients to avoid the short and long term consequences of an unnecessary Axillary 
Lymph Node Dissection (ALND), such as shoulder stiffness and lymphoedema, introducing the 
notion of axillary conservation for patients who have no disease in their axilla (1-3).  
Concurrently, neoadjuvant chemotherapy (NACT) has a continuously increasing role in a) 
converting inoperable to operable and b) downsizing the primary cancer to enable breast 
conserving surgery (BCS) in patients who would otherwise require a mastectomy. An area of 
current interest, however, is the management of the axilla in conjunction with NACT. SLNB can 
safely be offered after NACT to patients who were node negative at the outset (4-6). In women 
who have ultrasound guided biopsy-proven involved nodes at diagnosis, NACT results in a 
pathological complete response in the axilla more frequently than in the breast (7-9). Clinicians 
have been quick to recognise the benefit of downsizing the primary to permit breast conservation, 
but the possibility of downstaging the axilla to allow axillary conservation is not yet widely 
practised. 
There are already two prospective observational studies, the Alliance Z1071 and SENTINA trials 
(10, 11), reporting the False Negative Rate (FNR) of SLNB post NACT in initially node positive 
patients. The FNRs were 12.6 and 14.2% respectively, both above the current accepted cut off of 
10% (1). Reasons for the higher FNR include residual disease in the nodes, or fibrosis in response 
to treatment resulting in errant mapping to a normal but non-sentinel node. Both of these studies 
suggest that the dual localisation technique (with radioisotope and blue dye) and the number of 
harvested nodes increase the accuracy of SLNB in this particular group of patients but concerns 
persist about the safety of this approach.  
Axillary ultrasound (aUS) is widely used in the initial loco-regional staging of breast cancer and 
is accurate in this setting. The reported sensitivity (27%-94%) and specificity (53%-100%) vary 
widely (12, 13). Although the performance of aUS is operator-dependent, historically it has 
outperformed other imaging modalities in the axilla. The accuracy and FNR of aUS are improved 
by the additional testing of the lymph nodes identified on aUS by FNA cytology or core biopsy 
(10, 14-20). It has the added advantages of not involving ionising radiation, and is cost-effective 
(13). 
In an attempt to lower the FNR of SLNB after NACT, Boughey et al (14) reported the use of aUS 
after neoadjuvant chemotherapy and before surgery. However, the diagnostic accuracy of their 
aUS was low. Nonetheless, the selection of patients for SLNB by aUS resulted in a FNR for 
combined aUS and SLNB staging of 9.8%. They therefore propose the combined technique as a 
safe option for patients post NACT who were biopsy proven node positive at outset. Acceptable 
accuracy is difficult to define and was arbitrarily set at the same threshold of 10% in Z1071 as in 
NSABP-B32 (2, 3), though this may not be adequate in women such as those with triple negative 
cancers who have already received all of their systemic treatment, hence some of the concern 
about adopting this approach. 
The presentation of Z1071 and SENTINA at the San Antonio Breast Cancer Symposium in 
December 2012 (10, 11) led to a change of practice in our unit from an ad hoc comment at the 
time of re-evaluation of the breast lesion, to a formal radiological restaging of the axilla by aUS 
thereafter. This now includes a description of size and morphology and a comment on the number 
of residual abnormal lymph nodes. The aim of this study was to evaluate the diagnostic accuracy 
of aUS post NACT in women who were proven node positive at diagnosis since this change in 
practice.  
 
 
  
Patients & Methods 
Consecutive patients with proven axillary disease at diagnosis who received NACT and went on to 
ALND (our routine practice until December 2015) were identified from prospective Electronic 
Patient Records (EPR). These were also used for retrospective collection of data. Patients were 
managed at one of three sites of the same Trust connected on the same database with uniform 
guidelines and overlapping multidisciplinary teams.  All patients had US for evaluation of 
response during NACT.      
There are no universally-agreed guidelines on imaging criteria for the abnormal lymph node. The 
widely accepted criteria, however, are a) eccentric or concentric cortical thickness >2.5mm, b) 
absent fatty hilum, c) rounded morphology and d) increased blood flow in the thickened cortex on 
Doppler (12, 21). Ultrasound is not accurate in the evaluation of fibrosis (21). All US studies were 
performed on one of four GE machines (LOGIQTM) with a 15MHz ultrasound probe at two sites 
by either a consultant breast radiologist (n=6) or specialist breast sonographer/radiographer (n = 
6).  
Post-NACT aUS reports were compared to the gold standard, which was the post NACT 
pathology report, classified as positive or negative for abnormal lymph nodes and residual disease 
respectively. Diagnostic characteristics of aUS were calculated. These results were used in 
conjunction with Boughey’s algorithm (14) (fig 2) to calculate the combined accuracy of aUS 
with SLNB as this is the clinically relevant result. Data were also collected on age, tumour 
phenotype, grade, stage, chemotherapy regime, and use of trastuzumab.  
  
Results 
Three hundred and eight patients were identified as fulfilling the eligibility criteria and had their 
preoperative aUS between January 2013 and December 2015. All of them were female with a 
mean age of 50 years (SD 10.2). 
The patient demographic data and clinico-pathological features shown in table 1, reflect the 
patient group in which NACT is used in our institution: the low grade, ER positive, Her2 negative 
cases make up a decreasing proportion, being replaced by a greater proportion of the other 
subtypes, particularly grade 3, triple negative or Her2 positive cases. All Her2 positive patients 
received trastuzumab and most received a taxane. 
 
      Jan 2013-Dec 2015      
No of patients 308 
Age 50 years (SD 10.1) 
ER+Her2- 100 (32.4%) 
ER+Her2+ 68 (22%) 
ER-Her2+ 48 (15.6%) 
ER-Her2- 92 (30%) 
Grade I 1 (0.35) 
Grade II 80 (26%) 
Grade III 227 (73.7%) 
IDC 296 (96%) 
ILC 6 (2%) 
Mixed 6 (2%) 
Inflammatory 29 (9.4%) 
EC-T 231 (75%) 
Taxanes 292 (94.8%) 
Herceptin 116 (37.7%) 
 
 
Table 1. Patient demographics and clinico-pathological features 
 
Most women underwent axillary ultrasound just after the second cycle of chemotherapy (mean 12.2 
weeks prior to surgery, range 7-17, 95% CI 8.1-16.2). A small number of patients (~10%) had a 
repeat ultrasound 1-2 weeks before surgery. The sensitivity and specificity of aUS were 71%and 88% 
respectively. The FNR was 29%. The Negative and Positive Predictive Values (NPV and PPV) were 
83% and 79% respectively. The accuracy of the technique was 82% (Table 2).  
 
Jan 13-Dec 15 
n=308 
Axillary USS - 
residual disease 
Axillary USS - 
no residual 
disease 
 
No pCR 
True positive 
TP = 85 
False negative 
FN = 35 
Sensitivity 
= 71% 
pCR 
False positive 
FP = 22 
True negative 
TN = 166 
Specificity 
= 88% 
Accuracy = 
82% 
Positive 
predictive value 
= 79% 
(precision) 
Negative 
predictive value 
= 83% 
FNR = 
29% 
 
  
Table 2: Diagnostic characteristics of aUS. 
pCR = pathological complete response 
        
The diagnostic accuracy of the aUS is also illustrated  by the receiver-operator characteristic (ROC) 
curve(22) (Figure 1). The area under the curve (AUC) was 0.80.  
 
 
AUC = 0.8 
Fig. 1: ROC curve to illustrate sensitivity and specificity. 
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Tumour biology plays a key role in response to treatment so diagnostic characteristics were also 
calculated for the various phenotypes of tumours. Negative and Positive Predictive Values are the 
characteristics most easily understood as they indicate the chance of a correctly positive or 
negative answer, hence guiding axillary management. These are shown in Table 3. There was a 
notable variation in NPV and PPV according to phenotype, with Her2 positive cases having a 
higher NPV and more modest PPV, while Her2 negative cases had a higher PPV and more 
modest NPV. 
ER+Her2- 90% 69% 
ER+Her2+ 67% 87% 
ER-Her2+ 50% 90% 
ER-Her2- 81% 80% 
 
Table 3: Diagnostic PPV and NPV according to phenotype.  
 
  
Discussion 
Surgical management of the breast post-NACT is tailored according to response. However, 
surgical management of the axilla in current standard practice is still determined by the nodal 
status at presentation (23).  
Axillary US has been used extensively and is now an established imaging tool to assess the axilla 
as part of the diagnostic evaluation of a suspicious breast mass and in patients with newly 
diagnosed breast cancer. In the post-neoadjuvant chemotherapy setting, it has already been shown 
that when combined with SLNB, the FNR falls below the arbitrary acceptable cut off of 10% (1, 
2, 14), but the diagnostic accuracy of aUS in Boughey’s study was only 52% If our data on the 
accuracy of aUS replace the results in the flowchart in figure 2 of Boughey’s paper on the subject 
(14), assuming the same SLNB FNR, the FNR of the combined procedure falls to 4% (Figure 2), 
indicating that aUS can help to identify patients who may benefit from SLNB in this setting.  
 
Fig. 2: FNR estimated with the improved aUS characteristics on SLNB-FNR of 12.6%. 
Implications of and strategies to avoid a false positive aUS result 
When evaluating a diagnostic test, it is important to consider the implications of a false-positive 
or false negative result. In this scenario, the 21% of patients whose positive test result is false will 
be advised to have an ALND, which would then be negative. Thus they would be treated as is 
currently standard, with oncological safety, but adverse consequences in terms of lymphoedema 
and shoulder dysfunction. Conversely, the 79% majority with residual disease have moved 
directly to their definitive axillary treatment. 
In the early breast cancer setting, fine needle aspiration cytology, or core biopsy of the abnormal 
looking nodes is performed before committing a patient to ALND (2, 24-28). This could be 
considered here, in order to minimise the possibility of a second operation, though the volume of 
residual disease may lead to sampling errors and cytology may be hard to interpret post 
chemotherapy. Nonetheless, a false negative axillary cytology would be followed by surgical 
axillary staging in the form of SLNB, which provides a safety net.  
One limitation of our study was that the ultrasound was performed at the time of breast 
ultrasound, often after only the second cycle of chemotherapy. Some patients, particularly the 
Her2 positive cases who had a PPV of only 50-67% must have achieved their pCR in the 
subsequent weeks of treatment. The false positive rate of aUS is therefore likely to be reduced if a 
final aUS is performed after completion of NACT, and this is now our practice. The optimal 
timing has yet to be determined in order to achieve maximum accuracy of axillary re-staging 
through US imaging.  
 
Implications of and strategies to avoid a false negative aUS and SLNB post-NACT 
A false negative aUS result would lead clinicians to offer a patient SLNB. An estimated 86% of 
women with residual axillary disease would be identified by SLNB and managed accordingly. A 
false negative SLNB has greater potential implications for patients. It means that residual disease 
is present in a patient thought to have a pCR in the axilla while also implying understaging of the 
axilla, potentially affecting adjuvant treatment decisions. When patients are selected for SLNB 
using aUS of the diagnostic accuracy that we report, the combined FNR is estimated at 4%. In the 
post-NACT scenario, most patients with a false negative result will have ongoing systemic 
therapy in the form of trastuzumab and / or endocrine therapy. The timing of surgery after 
chemotherapy is historical, but it is possible that, after a further 14 doses of trastuzumab, any 
residual disease in the axilla would have been eradicated. Eradication may be less likely in 
women undergoing treatment for ER positive Her2 negative disease, but loco-regional control is 
likely with long-term endocrine therapy. Lack of clinically meaningful response in the breast 
means they are making up a decreasing proportion of our neoadjuvant chemotherapy population. 
Furthermore, based on our results according to phenotype, these patients will be largely protected 
by a high PPV such that only a small proportion will be offered SLNB. For patients with triple 
negative breast cancer and residual disease in the axilla no further adjuvant systemic treatment 
will be planned (though the lower axilla may be within the radiotherapy fields in those receiving 
whole breast or post-mastectomy radiotherapy). This subgroup of patients exhibits a high PPV 
and NPV. Risk of axillary recurrence should be taken in context of risk of distant disease. Since 
pCR is associated with better prognosis, those with a false negative SLNB have, by definition, not 
had a pCR and distant disease may manifest prior to any axillary recurrence. Nonetheless, the 
level of concern about false negative results should be higher for these women and the thresholds 
for treatment, perhaps, lower. 
Options to reduce the false negative rate include use of dual localisation (radioisotope and blue 
dye) and removal of at least 3 lymph nodes, but the logical step would be to ensure removal of the 
node, which was originally proven to be abnormal. One technique which is being used to ensure 
identification of the initial positive (index) node is targeted axillary dissection (TAD). This 
involves the pre-NACT marking of the positive node with subsequent post NACT retrieval of that 
specific “index” node along with the lymph nodes obtained with the standard SLNB localisation 
(15) (29). Placing radioactive iodine seeds or metal markers in the nodes have been suggested but 
are not yet widely accepted, because of the learning curve associated with these techniques (15, 
29). 
 The ACOSOG Z0011 study (30-33) led clinicians treating breast cancer to question the role of 
axillary treatment as residual disease does not, even at 10 years follow up (34), appear to result in a 
considerable risk of loco-regional or distant relapse. In an editorial (35) commenting on Z1071, it 
is also suggested that “in patients already committed to NACT, axillary recurrence is probably the 
most meaningful outcome measure and not the FNR”. A recent publication by Galimberti et al (17) 
provides reassuring oncological outcome data on 147 women who had SLNB post NACT without 
specific marking or retrieval of the index node. Seventy had a negative SLNB and did not receive 
any further axillary treatment.  After a median of 61 months follow up none of these women had 
presented with an axillary recurrence while one of the 77 women with a positive SLNB and ALND 
did recur in the axilla. Further work is required in this area to quantify the risk of axillary 
recurrence in the different phenotypes. 
 
  
Conclusion  
Axillary US is a widely available, reliable test to guide the surgical management of the axilla 
post-NACT in women who were node positive at diagnosis. While not adequate to re-stage the 
axilla in its own right, it has negative and positive predictive values which are clinically 
meaningful in assisting surgical decision-making and, when combined with SLNB, has an 
acceptable FNR. An attempt at axillary conservation should be offered to women, identified by 
aUS, who are likely to be among the 61% of patients who have achieved an axillary pCR, 
allowing them to potentially avoid the morbidity of ALND.   
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